// App-Quantinova.ai

593.0 : Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

Researchers

Presenter

  • Johanna C. Bendell

Principal Investigators

  • Bert H. O'Neil

  • Alexander Starodub

  • Derek J. Jonker

  • Thorvardur Ragnar Halfdanarson

  • William Jeffery Edenfield

  • Bassel F. El-Rayes

  • Joleen Marie Hubbard

  • Henry C. Pitot

  • Timothy J. Hobday

  • Youzhi Li

  • Yuan Gao

  • Axel Grothey

  • Laura Borodyansky

  • Chiang Li

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Indiana University Health Center for Cancer Care, Goshen, IN

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Mayo Clinic, Rochester, MN

  • Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN

  • Boston Biomedical Inc., Cambridge, MA

  • Boston Biomedical Inc., Cambridge, MA

Locations

  • United States

  • Canada

Companies

  • Boston Biomedical, I

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Phosphorylated signal transducer and activator of transcription 3

Drug/Treatment

  • Bevacizumab

  • Napabucasin

  • Irinotecan

  • leucovorin

  • BBI-608

  • FOLFIRI

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02024607

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved